333 related articles for article (PubMed ID: 26329812)
1. Dosing of rivaroxaban by indication: getting the right dose for the patient.
Escolar G; Carne X; Arellano-Rodrigo E
Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
[TBL] [Abstract][Full Text] [Related]
2. Rivaroxaban for the treatment and prevention of thromboembolic disease.
Antoniou S
J Pharm Pharmacol; 2015 Aug; 67(8):1119-32. PubMed ID: 26059702
[TBL] [Abstract][Full Text] [Related]
3. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
Cheng JW; Barillari G
J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
[TBL] [Abstract][Full Text] [Related]
4. Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications.
Kubitza D; Berkowitz SD; Misselwitz F
Clin Appl Thromb Hemost; 2016 Jul; 22(5):412-22. PubMed ID: 26893445
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
Kreutz R
Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
Tellor KB; Patel S; Armbruster AL; Daly MW
J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
[TBL] [Abstract][Full Text] [Related]
8. Dose-finding study of rivaroxaban in hemodialysis patients.
De Vriese AS; Caluwé R; Bailleul E; De Bacquer D; Borrey D; Van Vlem B; Vandecasteele SJ; Emmerechts J
Am J Kidney Dis; 2015 Jul; 66(1):91-8. PubMed ID: 25804678
[TBL] [Abstract][Full Text] [Related]
9. Practical management of rivaroxaban for the treatment of venous thromboembolism.
Imberti D; Benedetti R
Clin Appl Thromb Hemost; 2015 May; 21(4):309-18. PubMed ID: 24057396
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
11. Appropriateness of Dabigatran and Rivaroxaban Prescribing in Qatar: A 5-Year Experience.
Elewa H; El-Makaty H; Ali Z
J Cardiovasc Pharmacol Ther; 2018 Mar; 23(2):155-161. PubMed ID: 28978236
[TBL] [Abstract][Full Text] [Related]
12. Management of Bleeding Associated with New Oral Anticoagulants.
Franchini M; Bonfanti C; Mannucci PM
Semin Thromb Hemost; 2015 Oct; 41(7):788-801. PubMed ID: 26408923
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Eur J Haematol; 2015 Nov; 95(5):389-404. PubMed ID: 26095540
[TBL] [Abstract][Full Text] [Related]
14. Overview of Current Evidence on the Impact of the Initial High Dose of the Direct Factor Xa Inhibitor Rivaroxaban on Thrombus Resolution in the Treatment of Venous Thromboembolism.
Bauersachs R; Koitabashi N
Int Heart J; 2017 Feb; 58(1):6-15. PubMed ID: 28123163
[TBL] [Abstract][Full Text] [Related]
15. Drug-drug interactions of non-vitamin K oral anticoagulants.
Voukalis C; Lip GY; Shantsila E
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1445-1461. PubMed ID: 27535163
[TBL] [Abstract][Full Text] [Related]
16. [Contemporary approaches to determine the duration of anticoagulant therapy for venous thromboembolism].
Lobastov KV
Khirurgiia (Mosk); 2019; (5):94-103. PubMed ID: 31169827
[TBL] [Abstract][Full Text] [Related]
17. Rivaroxaban for prevention and treatment of venous thromboembolism.
Chan NC; Weitz JI
Future Cardiol; 2019 Mar; 15(2):63-77. PubMed ID: 30779598
[TBL] [Abstract][Full Text] [Related]
18. Management of rivaroxaban in relation to bodyweight and body mass index.
Uprichard J
Ther Adv Cardiovasc Dis; 2016 Oct; 10(5):294-303. PubMed ID: 27090286
[TBL] [Abstract][Full Text] [Related]
19. Rivaroxaban in the treatment of venous thromboembolism and the prevention of recurrences: a practical approach.
Arcelus JI; Domènech P; Fernández-Capitan Mdel C; Guijarro R; Jiménez D; Jiménez S; Lozano FS; Monreal M; Nieto JA; Páramo JA
Clin Appl Thromb Hemost; 2015 May; 21(4):297-308. PubMed ID: 25504999
[TBL] [Abstract][Full Text] [Related]
20. Effect of extremes of body weight on drug level in patient treated with standard dose of rivaroxaban for venous thromboembolism; real life experience.
Arachchillage D; Reynolds R; Devey T; Maclean R; Kitchen S; van Veen JJ
Thromb Res; 2016 Nov; 147():32-35. PubMed ID: 27669125
[No Abstract] [Full Text] [Related]
[Next] [New Search]
